Multidrug-Resistant Gram-Negative Bacteria Infections: Current Epidemiology, Prognosis and Treatment Options
This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Special Issue Information
Dear Colleagues,
In the rapidly evolving world of infectious diseases, multidrug-resistant Gram-negative bacteria (MDR-GNB) infections present significant threats to global public health. Understanding the prognosis and outcomes of MDR-GNB infections is crucial for healthcare providers and policymakers alike.
In this Special Issue, we welcome scholars to explore current epidemiology, prognosis, and treatment options for these infections, including but not limited to those caused by Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
Areas of interest include:
- The latest advances in understanding the mechanisms of resistance and transmission dynamics, as well as novel approaches to combatting these pathogens.
- Evaluation of the efficacy of existing treatment options and the exploration of emerging strategies to effectively prevent and manage these infections.
- Addressing the need for enhanced surveillance and rapid diagnostic methods to monitor the spread of multidrug-resistant Gram-negative bacteria and support optimal clinical decision making in the optimization of treatment plans.
This Special Issue will serve as a valuable resource for clinicians, researchers, and policymakers striving to reduce the impact of drug resistance on global health.
Dr. Novella Carannante
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug-resistant gram-negative bacteria
- epidemiology and prognosis
- antibiotic treatment options
- antimicrobial resistance
- infection control and antibiotic use
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Published Papers
Antibiotics - ISSN 2079-6382